Novo Nordisk's Wegovy Gets EU Regulator Endorsement to Reduce Heart Risks -- Update
Will it break the duopoly monopoly? The "new star" of weight loss drug Viking's stock price has doubled 2.4 times this year.
Eli Lilly and Co's market cap evaporated by 120 billion US dollars.
Novo Nordisk Shares Decline Amid Competitive Pressure
Is the weight loss drug industry about to change? Viking Therapeutics rose nearly 40% intraday and hit a two-month high.
After communicating with the regulatory institution FDA, USA's Viking Therapeutics is pushing forward the weight-loss candidate drug VK2735 to phase III clinical trials ahead of schedule, potentially bringing the launch time forward by one year. This drug is expected to be injected once a month, which is more convenient than the same miraculous drug from Eli Lilly and Co and Novo Nordisk A/S. The oral version of VK2735 will start mid-term trials in the fourth quarter of this year.
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
Novo Nordisk's weight loss drug Wegovy has received approval from the European Union and can reduce the risk of major heart diseases by 20%.
According to a press release by novo-nordisk a/s, the european medicines agency (EMA) supports the company's use of the weight-loss drug Wegovy to reduce the risk of stroke and heart disease. Analysis suggests that this significantly expands the potential number of benefiting patients.
Novo Nordisk Wins EU Backing for Wegovy Label Update
European Equities Traded in the US as American Depositary Receipts Trend Slightly in Thursday Trading
Viking Speeds Development Its Weight-Loss Pill -- Barrons.com
Roche's CEO stated that their weight-loss medication trial has had positive results and will become a competitor to Wegovy.
Roche Pharmaceuticals said on Thursday that its weight-loss drugs, as a competitor to Novo Nordisk's famous Wegovy, will also be part of a set of drugs aimed at combating the impact of obesity and sharing a slice of the market for anti-obesity drugs. Thomas Schinecker, CEO of Roche Pharmaceuticals, welcomed the positive early results of the company's two weight-loss candidate drugs, which he believes show the 'best weight-loss potential.' He added that Roche Pharmaceuticals' weight-loss drugs will be part of a wider range of weight-loss product offerings that will help the Swiss pharmaceutical giant compete in the growing market for obesity drugs.
Novo Nordisk's Options Frenzy: What You Need to Know
Express News | Eli Lilly and Novo Nordisk Shares Are Trading Lower After Competitor Viking Announced the Advancement of Its Obesity Candidate
The “up-and-coming diet drug” Viking (VKTX.US) drug enters the late stages of development, and the “Nolie” stock price fell in shock
As the Viking diet pill entered the later stages of clinical trials, Eli Lilly and Novo Nordisk stock prices declined.
Viking Sends Lilly, Novo Lower as Obesity Drug Enters Late-stage Program
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Novo Nordisk's (NVO.US) weight-loss drug, Wegovy, has been approved by UK regulatory authorities and can be used to treat heart disease.
Following the United States, the regulatory authority in the United Kingdom has also approved the expansion of the application scope of Novo Nordisk's (NVO.US) weight loss drug Wegovy to treat heart disease.
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
Novo Nordisk's Wegovy Gets UK Approval as Preventative Treatment for Heart Problems in Obese, Overweight Adults
Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors